Sands Capital led Cytovale’s $100 million Series D funding round, enabling commercial and operational expansion of IntelliSep, a rapid diagnostic test cleared by the Federal Drug Administration (FDA), that is transforming sepsis care for hospital emergency departments and health systems nationwide.

This latest funding will help enable the company’s continued growth, enhanced processes, upgraded tooling, expanded infrastructure, and increased supply chain resiliency.

The United Kingdom’s Financial Reporting Council has named Sands Capital as a signatory to the UK Stewardship Code for the second year in a row. The UK Stewardship Code was designed to strengthen reporting requirements and stewardship expectations for asset managers, asset owners, and service providers.

Managing a team of analysts is no easy task, explains Michael Raab. It’s a diverse opinionated group charged with creating the investment ideas that can add value for clients. Cultivating a culture that supports this creativity is an ongoing endeavor.

Talented students from universities across the country will be supporting the investment, operations, and client service teams as part of Sands Capital’s summer internship program.

Sands Capital closed Pulse Fund III, securing $555 million to invest in groundbreaking therapeutics, diagnostics, and life sciences tools with the potential to advance disease understanding and treatment.

Stewardship is most effective when linked to a core investment philosophy. In our 2023 stewardship report, we illustrate how we align our ESG work to achieve an approach that is value driven, long-term oriented, and horizontally integrated.

At Sands Capital, we believe effective stewardship is value-driven, long-term oriented, and horizontally integrated. Read highlights from Sands Capital Director of Stewardship Karin Riechenberg's discussion at the Council of Institutional Investors Spring Conference.